IXICO plc Board changes (9945J)
September 16 2016 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 9945J
IXICO plc
16 September 2016
IXICO plc
('IXICO' or the 'Company')
Board changes
London, UK, 16 September 2016: IXICO plc (Ticker: IXI), the
brain health company, today announces the following changes to the
Board, all of which take immediate effect:
Dr Andy Richards has elected to step down from the Board to
focus on his other commitments. Andy has been Chairman of IXICO
since 2009 and has guided the Company through its formative years.
In particular, Andy's vision and enthusiasm for the deployment of
technological innovations in the healthcare industry to realise the
potential for digital healthcare has been central in developing
IXICO into the business it is today.
Charles Spicer has succeeded Andy as Non-Executive Chairman.
Charles was an executive Director of IXICO between July 2013 and
January 2016 with a focus on corporate strategy. He became a
Non-Executive Director of IXICO in January 2016. He has a wealth of
experience working for, and as advisor to, public and private
companies primarily in the medtech and life science sectors.
Charles is currently Chairman of an NIHR Invention for Innovation
(i4i) funding panel and is also Non-Executive Chairman of PuriCore
Plc, 11 Health & Technologies Limited and Creo Medical
Limited.
In addition, Mark Warne joins the Board as a Non-Executive
Director. He is Head of the Healthcare division of IP Group Plc
(LSE: IPO) which, at the end of December 2015, had shareholdings in
31 companies valued at over GBP275 million. Mark previously acted
as the power of attorney for corporate director IP2IPO Services
Limited of Optimal Medicine Limited and was instrumental in the
sale of the business to IXICO. As part of that acquisition and the
participation of IP Group Plc in the financing round completed in
December 2015, IP Group has a 20.25% shareholding in the Company.
Mark brings a wealth of technology commercialisation experience to
support IXICO through its next stage of product development and
value creation. Mark has been at IP Group since 2008 and represents
it on the boards of several portfolio companies, both quoted and
private. He has extensive experience in building and growing
healthcare businesses as well as in managing transactions including
portfolio company IPOs, financings and M&A.
Mark will join the Remuneration Committee which is chaired by
Tim Sharpington and the Audit Committee which is chaired by John
Bradshaw.
David Brister, who joined the Board following the acquisition of
Optimal Medicine Limited, stepped down as a Non-Executive Director
having helped oversee the successful integration of this
acquisition.
Derek Hill, Chief Executive Officer of IXICO, said:
"We are grateful to Andy Richards for the huge contribution he
has made to IXICO. He set the vision for IXICO's development into a
digital healthcare company for brain health, identifying the
opportunities to raise growth capital through admission onto AIM in
2013, and the acquisition of Optimal Medicine in 2015."
Mark Warne, Non-Executive Director of IXICO and Head of
Healthcare at IP Group plc, said:
"I am excited to be joining the board of IXICO and I see
significant potential for it to lead in the CNS and behavioural
health fields in the rapidly growing digital health market. Its
team is highly respected by industry and government for its brain
health specialisation and the Company has some fantastic
technologies. I would also like to take this opportunity to thank
David Brister for his recent contribution to IXICO and prior
contribution as Chairman at Optimal Medicine where IP Group was a
shareholder".
Enquiries:
IXICO plc +44 20 3763 7499
Derek Hill, CEO
Susan Lowther, CFO
Peel Hunt LLP (Nominated
Adviser) +44 20 7418 8900
James Steel / Oliver Jackson
FTI Consulting Limited
(Investor Relations)
Simon Conway / Mo Noonan
/ Matthew Moss +44 20 3727 1000
Additional Information:
The following further information regarding the appointment of
Mark Robert Warne, aged 41, is disclosed under Schedule 2(g) and
Rule 17 of the AIM Rules for Companies:
(i) Mark Warne is currently a director or partner of:
Capsant Neurotechnologies Limited
Cronin Group plc
Crysalin Limited
Genomics plc
hVIVO plc
Oxford CADD Limited
(ii) in the last five years, Mark Warne has been but is no
longer a director or partner of the following companies or
partnerships:
31 Howard Road Management Limited
Bristol Innovations Limited
Genomics Limited
OM France SARL
Optimal Medicine Inc.
Oxtox Limited
(iii) in the last five years, Mark Warne has acted as a power of
attorney for corporate director IP2IPO Services Limited to the
following companies:
InhibOx Limited
Optimal Medicine Limited
Activiomics Limited
Ubiquigent Limited
Azellon Limited
Cronin3D Limited
Mode Diagnostics Limited
Mode Health Limited
(iv) Mark Warne holds 4,323 ordinary shares in his own name and
has an indirect interest in IP2IPO's and the NETF shareholdings in
IXICO plc.
Mark Warne has confirmed that there is no other additional
information to be disclosed under Schedule 2 (g) of the AIM
Rules.
About IXICO
IXICO's innovative and proprietary digital healthcare
technologies help those involved in researching and treating
serious diseases to capture and analyse clinical data to make
rapid, informed decisions. In clinical research this includes the
phenotyping of patients, quantification of disease pathology and
measurement of patient outcomes. In clinical practice the mobile
health and digital decision support technologies aid diagnosis,
patient engagement and monitoring. IXICO is also collaborating with
partners to develop companion digital health products targeted at
improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease,
Huntington's disease, multiple sclerosis, behavioural health, child
and adolescent mental health. More information is available on
www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAAKPDPPBKDPCD
(END) Dow Jones Newswires
September 16, 2016 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024